Andrew Spencer, MBBS, FRACP, FRCPA, DM, discusses the potential role for in vivo CAR T-cell therapy in relapsed/refractory multiple myeloma.
Andrew Spencer, MBBS, FRACP, FRCPA, DM
Advertisement
Articles by Andrew Spencer, MBBS, FRACP, FRCPA, DM
Andrew Spencer, MBBS, FRACP, FRCPA, DM, discusses efficacy data for the in vivo CAR T-cell therapy KLN-1010 in multiple myeloma.
Andrew Spencer, MBBS, FRACP, FRCPA, DM, discusses key features of in vivo CAR T-cell therapy in multiple myeloma.
Andrew Spencer, MD, MBBS, FRACP, FRCPA, discusses the rationale to evaluate panobinostat in multiple myeloma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC
3
NMPA Accepts Toripalimab Plus Chemotherapy Application for Expanded Stage II-III NSCLC Use
4
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
5